BioTech 365

MARCH 12, 2021

Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V. Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. BERWYN, Pa.–(BUSINESS

Licensing 40

Licensing Licensing Generic Pharmaceutical Development 40

Pharmaceutical Technology

SEPTEMBER 22, 2022

The current standards of care (SOCs) in OA focus on symptom management and are made up of generic pharmaceuticals, including nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, antidepressants, and intra-articular injections. OA is considered to be a heterogeneous disease with a complicated pathophysiology and unclear aetiology.

Marketing 147

Marketing Generic Pharmaceutical Clinical Trials Clinical Trials 147

Pharmaceutical Technology

SEPTEMBER 23, 2022

For pharma and biotech companies, there are many advantages to partnering with a Contract Development and Manufacturing Organisations (CDMO): they can access more specialized knowledge, state-of-the-art equipment, and qualified staff, as well as reduce their total cost of ownership, all while maintaining speed to market.

Manufacturing 147

Manufacturing Drugs Production Development 147

BioTech 365

AUGUST 4, 2021

the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → Chino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.

Manufacturing 40

Manufacturing Generic Pharmaceutical Production Development 40

Pharmaceutical Technology

FEBRUARY 18, 2023

The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress. Gevokizumab Overview Gevokizumab (XOMA-052) is developing gevokizumab for the treatment of metastatic colorectal cancer gastroesophageal cancer and colon cancer. It is a new molecular entity (NME).

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. nAMD accounts for 10% of all age-related macular degeneration cases, but is responsible for 90% of AMD-related blindness 2 ,” said Florian Bieber, Global Head of Biopharmaceuticals Development, Sandoz.

Clinical Development 52

Clinical Development Medicine Development Containment 52

The Pharma Data

MAY 2, 2021

Holzkirchen, May 3, 2021 – Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. The initiation of this study marks an important milestone in the development of our biosimilar aflibercept. Aflibercept is a key treatment in ophthalmology.

Clinical Development 40

Clinical Development Medicine Development Production 40

The Pharma Data

JANUARY 4, 2021

for expanding activities in the US with its initial focus on facilitating clinical development. Burr Boulevard, Teaneck, NJ 07666 (3) President: Yasushi Miyazawa (4) Scope of business: Clinical research and development (5) Paid in capital: US$100,000. (2) Location: 500 Frank W.

Generic Pharmaceutical 40

Generic Pharmaceutical Generic Drugs Clinical Development Clinical Research 40

The Pharma Data

JUNE 17, 2022

At Sandoz, we are constantly looking for ways to meet the changing needs of patients and health care providers,” said Florian Bieber, Global Head Biopharmaceuticals Development, Sandoz. “By About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

Medicine 52

Medicine Generic Pharmaceutical FDA Approval Packaging 52

The Pharma Data

MARCH 15, 2022

Agency Supports Development of Complex Generic Drug-Device Combination Product to Improve Competition and Access to More Affordable Medicines. The FDA regularly takes steps to help guide industry through the development process for generic drug products, including combination products, such as MDIs, that consist of a drug and a device.

FDA Approval 52

FDA Approval Generic Drugs Production Drugs 52

The Pharma Data

MAY 31, 2022

These include ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development. Act4Biosimilars is supported by founding sponsor Sandoz, a pioneer and global leader in biosimilars, who developed and brought the first biosimilar medicine to patients 16 years ago.

Medicine 52

Medicine Generic Pharmaceutical Development Sales 52

The Pharma Data

OCTOBER 26, 2021

Sandoz is a global leader in generic pharmaceuticals and biosimilars. Its global portfolio covers all major therapeutic areas with a global market leadership position in biosimilars, generic antibiotics and oncology medicines. About 108,000 people of more than 140 nationalities work at Novartis around the world.

Medicine 52

Medicine Sales Marketing Clinical Trials 52

The Pharma Data

MAY 18, 2021

Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical needs. Our ambition is to be the world’s leading and most valued generics company.

Manufacturing 40

Manufacturing Production Containment Generic Pharmaceutical 40

The Pharma Data

MAY 15, 2023

The Sandoz Board of Directors will have 10 members in total and 3 sub-committees: a Science, Innovation & Development Committee, a Human Capital & ESG Committee and an Audit, Risk & Compliance Committee. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development.

Sales 40

Sales Production Doctor Doctors 40

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

DECEMBER 22, 2022

The funding will offer capital to extend Blueprint’s varied pipeline toward marketing as well as to continue seeking strategic and synergistic business development prospects. billion to expedite research and development (R&D) for infectious diseases in lower-income countries. Innovation.

Insulin 130

Insulin Production Development Genetics 130

XTalks

JUNE 8, 2022

Sandoz is a pioneering leader in generic pharmaceuticals and biosimilars, as Sandoz launched the world’s first biosimilar in Europe in 2006 and won the first biosimilar approval in the US in 2014. Among them are “ensuring equitable pricing, involving patients in treatment decisions and streamlining biosimilar development.”.

Generic Pharmaceutical 69

Generic Pharmaceutical Production Medicine Branding 69

The Pharma Data

NOVEMBER 5, 2020

About Senores Pharmaceuticals Pvt. Senores Pharmaceuticals is an Ahmedabad, India based R&D partner and an affiliate of Aavis Pharmaceuticals. It is involved in product development and marketing in the USA and ROW markets. About Jubilant Cadista Pharmaceuticals Inc. Jubilant Cadista Pharmaceuticals Inc.

Marketing 40

Marketing Generic Pharmaceutical Contract Manufacturing Manufacturing 40

The Pharma Data

OCTOBER 27, 2020

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. A playback of the call will be archived and accessible on the same website for at least three months. About Lannett Company, Inc.

Generic Pharmaceutical 40

Generic Pharmaceutical Packaging Packaging Manufacturing 40

The Pharma Data

APRIL 4, 2023

It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development. About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our ambition is to be the world’s leading and most valued generics company.

Medicine 40

Medicine Generic Pharmaceutical FDA Approval Marketing 40

Pharma in Brief

DECEMBER 3, 2023

The Regulations became a moving target for the innovative and generic pharmaceutical industries, being amended seven times between 1998 and 2016. Further information We provide updates on the Regulations and other industry developments here at Pharma in Brief. Frequent amendments (1998–2016).

Regulation 52

Regulation Compliance Medicine Manufacturing 52

FDA Law Blog

JANUARY 24, 2024

Biotechnology and Biomanufacturing; Harnessing Research and Development to Further Societal Goals.” As the report explains: This report provides a vision for harnessing research and development (R&D) advances in biotechnology and biomanufacturing to build supply chain resilience. bioeconomy.”

Manufacturing 69

Manufacturing Drugs Generic Pharmaceutical Production 69

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. Aurobindo Pharma and COVAXX are partnering on clinical development, manufacturing and marketing of COVAXX’s vaccine candidate, UB-612. ” .

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

The Pharma Data

DECEMBER 23, 2020

company developing UB-612 a multitope peptide-based vaccine to fight COVID-19, today announced an exclusive agreement with Aurobindo Pharma to expand its global development and commercialization of UB-612 to India and the United Nations Children’s Fund (UNICEF) agency. Commenting on the development, Mr. N. HAUPPAUGE, N.Y.–(

Vaccination 52

Vaccination Vaccine Manufacturing Antibody 52

Pharmaceutical Technology

MARCH 22, 2023

In the 1990s, generic pharmaceutical companies in the European Union (EU) offshored the manufacturing of active pharmaceutical ingredients (API) primarily to China. Koen Berden, executive director of international trade at the International Federation of Pharmaceutical Industries and Associations (EFPIA), in an interview.

Production 263

Production Manufacturing Drugs Generic Drugs 263